Session Type: Poster Session Number: 340 Session Title: Software Tools: Analysis I Session Date and Time: 10/21/2019 8:00:00 AM – 10/21/2019 12:00:00 PM Location/Room: McCormick Place: Hall A
Presentation Time: 10/21/2019 11:00:00 AM – 10/21/2019 12:00:00 PM Presentation Number: 340.16 Poster Board Number: CC73 Abstract Control Number: 14195
Poster boards are six feet (1.8 m) wide and four feet (1.2 m) high. More information on preparing your poster, including poster templates, can be found on SfN.org. Poster templates are provided as guidelines for creating a poster. Posters are not required to follow a particular format. They should follow requirements for scientific rigor, outlined below.
Layout (4 column)
Title: Prepare a banner for the top of the poster indicating the abstract title, author(s), affiliation(s), and the presentation number. Use lettering at least one-inch high.
Illustrations: Design figures for viewing from a distance and use clear, visible graphics and large type. Colors are effective if used sparingly; use dark colors on white or pale backgrounds and light colors on dark backgrounds. Figures should illustrate no more than one or two major points. However, simple figures are unnecessary. Make clear main points, but include detail for the aficionado. Indicate illustration sequences with numbers or letters at least one inch high. (Omit “Fig.” or “Figure.” This is unnecessary and occupies excess space).
Each figure or table should have a heading of one or two lines in very large type stating the “take-home” message. Provide additional essential information below in a legend set in 16 point or larger type.
Minimize narrative. Integrate text that would normally appear in the body (Results and Discussion) of a manuscript in figure legends. Concisely describe not only the content of the figure, but also the derived conclusions. Place brief details of methodology at the end of each legend.
Use large type in short, separated paragraphs with unjustified (ragged right) margins. Numbered or bulleted lists are effective ways to convey a series of points. Do not set entire paragraphs in uppercase (all capitals) or boldface type.
Place an introduction at the upper left and a conclusion at the lower right, both in large type. It is rarely necessary to post a copy of the abstract.
Bruker Biospin 9.4T scan- ner (Bruker Medizintechnik, Karlsruhe, Germany) equipped with an actively shielded gradient coil. A quadrature volume transmitter coil (model: MT0381, inner diameter=86mm) was used for RF excitation. An actively-decoupled surface coil (model: MT0105-20) was placed di
Talk, lecture (clustering) meetings with David Knudsen, Jo-Ann Brown, Ania Harlick, Lunch with students Richard Frayne
# Day 2 schedule
Group questions: funding. research. impact. teaching. outreach meetings with Wilten Nicola, Jorn Davidsen Lunch with David Feder, David Hobil, Ania. Penetrating ground radio Meetings with Christoph Simon, David Feder, David Hobil
How you prepare for chemotherapy depends on which drugs you’ll receive and how they’ll be administered. Your doctor will give you specific instructions to prepare for your chemotherapy treatments. You may need to:
Have a device surgically inserted before intravenous chemotherapy. If you’ll be receiving your chemotherapy intravenously — into a vein — your doctor may recommend a device, such as a catheter, port or pump. The catheter or other device is surgically implanted into a large vein, usually in your chest. Chemotherapy drugs can be given through the device.
Undergo tests and procedures to make sure your body is ready to receive chemotherapy. Blood tests to check kidney and liver function and heart tests to check for heart health can determine whether your body is ready to begin chemotherapy. If there’s a problem, your doctor may delay your treatment or select a different chemotherapy drug and dosage that’s safer for you.
See your dentist. Your doctor may recommend that a dentist check your teeth for signs of infection. Treating existing infections may reduce the risk of complications during chemotherapy treatment, since some chemotherapy may reduce your body’s ability to fight infections.
Plan ahead for side effects. Ask your doctor what side effects to expect during and after chemotherapy and make appropriate arrangements. For instance, if your chemotherapy treatment will cause infertility, you may wish to consider your options for preserving your sperm or eggs for future use. If your chemotherapy will cause hair loss, consider planning for a head covering.
Make arrangements for help at home and at work. Most chemotherapy treatments are given in an outpatient clinic, which means most people are able to continue working and doing their usual activities during chemotherapy. Your doctor can tell you in general how much the chemotherapy will affect your usual activities, but it’s difficult to predict exactly how you’ll feel.Ask your doctor if you’ll need time off work or help around the house after treatment. Ask your doctor for the details of your chemotherapy treatments so that you can make arrangements for work, children, pets or other commitments.
Prepare for your first treatment. Ask your doctor or chemotherapy nurses how to prepare for chemotherapy. It may be helpful to arrive for your first chemotherapy treatment well-rested. You might wish to eat a light meal beforehand in case your chemotherapy medications cause nausea.Have a friend or family member drive you to your first treatment. Most people can drive themselves to and from chemotherapy sessions. But the first time you may find that the medications make you sleepy or cause other side effects that make driving difficult.
Three of the drugs in R-CHOP are powerful cytotoxics, which means they kill cells. One is a type of immunotherapy and the last is a steroid, which has shown to have anticancer effects.
Rituximab is generally used to treat NHL. It’s a monoclonal antibody. It targets a protein called CD20 on the surface of white blood cells called “B cells. Once the drug attaches to the B cells, your immune system attacks and kills them.
This drug can treat a variety of cancers, including lymphoma and cancer of the breast and lung. Cyclophosphamide targets the DNA of cancer cells and signals them to stop dividing.
Doxorubicin hydrochloride (Adriamycin, Rubex)
This drug is an anthracycline that can treat many types of cancer, including breast, lung, and ovarian cancer. Doxorubicin blocks an enzyme cancer cells need to grow and reproduce. It’s bright red color has earned it the nickname “the red devil.”
Vincristine (Oncovin, Vincasar PFS, Vincrex)
Vincristine is an alkaloid that can treat many types of cancer, including advanced-stage breast cancer, lymphomas, and leukemia. It interferes with genes to stop them from replicating. This drug is a vesicant, meaning it can damage tissue and vessels.
This drug is a corticosteroid available under a variety of brand names. Unlike the others, this is an oral medication. It works with your immune system to help reduce:
low platelet levels, or thrombocytopenia
high calcium levels, or hypercalcemia
Together, these drugs create a potent cancer-fighting cocktail.
Journal of Hematological Oncology Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
The study did not meet its primary end point in the ITT or ABC population. However, in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety. In patients age 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes.
CBC (complete blood count)
Red blood cell count
Male: 4.35-5.65 trillion cells/L* (4.32-5.72 million cells/mcL**)Female: 3.92-5.13 trillion cells/L (3.90-5.03 million cells/mcL)
VTE: Venous Thromboembolic events DLBCL: Diffuse large B-cell lymphoma
DLBCL patients present a high risk of VTE, with approximately half of all VTE events occurring early in the course of the disease. We were able to identify the presence of bulky disease at diagnosis and the absence of response to first line therapy as risk factors for developing VTE. Te use of anthracycline-containing regimens was protective against VTE, likely because of the increased rates of disease response. Patients with VTE had worsened outcomes, likely a result of the presence of persistent disease, although a direct effect of VTE on long-term outcomes cannot be ruled out. Our results highlight the need for a heightened awareness of the increased risk of VTE in DLBCL patients and the need for prevention strategies.
Low‐molecular‐weight heparin (LMWH), when compared with warfarin, has been shown to reduce the risk of recurrent VTE in patients with cancer‐associated thrombosis (CAT),4 and is therefore the standard treatment for acute CAT for the past 15 years. However, the high cost and significant lifestyle burden associated with LMWH have led many clinicians and investigators to wonder whether the direct oral anticoagulants (DOACs) might be a better choice for primary and/or secondary VTE prevention in patients with cancer.
Based on the aggregate of available evidence, warfarin and other VKA should be a “third choice” for cancer patients, used only in situations where neither a DOAC nor LMWH is feasible.
direct oral anticoagulants :
Direct oral anticoagulants (DOAC)
Four DOACs have been approved for the treatment of DVT and/or PE, including dabigatran, rivaroxaban, apixaban, and edoxaban. All have demonstrated a comparable efficacy and safety to VKA in the cancer subpopulation.37 However, the cancer subpopulation enrolled in these large studies was small and generally had lower risks of both recurrent VTE and hemorrhage when compared with patients enrolled in earlier studies specific to cancer patients (such as CLOT study).38Meta‐analyses have suggested that DOACs and LMWH may have similar efficacy and safety in cancer patients, but these were based on indirect comparisons.38, 39 A few single‐center cohort studies of rivaroxaban for CAT have yielded encouraging results, but all had significant methodologic limitations.40, 41, 42, 43 A recent study explored the use of rivaroxaban in cancer patients with catheter‐related thrombosis also had promising results.44 Overall, these preliminary results are encouraging, but not definitive.
Low molecular weight heparin (wikipedia) Patients with cancer are at higher risk of venous thromboembolism and LMWHs are used to reduce this risk. The CLOT study, published in 2003, showed that, in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events. Use of LMWH in cancer patients for at least the first 3 to 6 months of long-term treatment is recommended in numerous guidelines and is now regarded as a standard of care.
Note (JJJ): Delteparin (Tinzaparin) and Nadroparin are better than Warfarin.
reference:  Nishioka J, Goodin S (2007). “Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival”. Journal of Oncology Pharmacy Practice. 13 (2): 85–97.doi:10.1177/1078155207079169. PMID17873108.
LMWH is also the favored treatment for cancer-related blood clots, since it has been shown to be more effective than warfarin (tablet).
LMWH is often used temporarily to help patients transition – or bridge – to long-term oral anticoagulant therapy, most commonly warfarin or Coumadin®. Your doctor will usually add warfarin to your medication schedule, so you take both warfarin and LMWH for several days under careful monitoring. Once your body achieves therapeutic blood levels of warfarin, your doctor will discontinue LMWH injections.
As with UFH, let your doctor know if you are taking aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs) – such as ibuprofen or naproxen – or clopidogrel before starting LMWH treatment, because these drugs increase the risk of bleeding.